KR102175929B9 - Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3a - Google Patents

Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3a

Info

Publication number
KR102175929B9
KR102175929B9 KR1020190017651A KR20190017651A KR102175929B9 KR 102175929 B9 KR102175929 B9 KR 102175929B9 KR 1020190017651 A KR1020190017651 A KR 1020190017651A KR 20190017651 A KR20190017651 A KR 20190017651A KR 102175929 B9 KR102175929 B9 KR 102175929B9
Authority
KR
South Korea
Prior art keywords
brn3a
diagnosis
treatment
composition
thyroid cancer
Prior art date
Application number
KR1020190017651A
Other languages
Korean (ko)
Other versions
KR20200099721A (en
KR102175929B1 (en
Inventor
구본석
정승남
장재원
류려화
오찬
원호륜
강예은
Original Assignee
충남대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 충남대학교 산학협력단 filed Critical 충남대학교 산학협력단
Priority to KR1020190017651A priority Critical patent/KR102175929B1/en
Publication of KR20200099721A publication Critical patent/KR20200099721A/en
Application granted granted Critical
Publication of KR102175929B1 publication Critical patent/KR102175929B1/en
Publication of KR102175929B9 publication Critical patent/KR102175929B9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804Nucleic acid analysis using immunogens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/12Post-translational modifications [PTMs] in chemical analysis of biological material alkylation, e.g. methylation, (iso-)prenylation, farnesylation
KR1020190017651A 2019-02-15 2019-02-15 Composition for diagnosis and treatment of thyroid cancer comprising Brn3a KR102175929B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190017651A KR102175929B1 (en) 2019-02-15 2019-02-15 Composition for diagnosis and treatment of thyroid cancer comprising Brn3a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190017651A KR102175929B1 (en) 2019-02-15 2019-02-15 Composition for diagnosis and treatment of thyroid cancer comprising Brn3a

Publications (3)

Publication Number Publication Date
KR20200099721A KR20200099721A (en) 2020-08-25
KR102175929B1 KR102175929B1 (en) 2020-11-06
KR102175929B9 true KR102175929B9 (en) 2022-05-10

Family

ID=72242032

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190017651A KR102175929B1 (en) 2019-02-15 2019-02-15 Composition for diagnosis and treatment of thyroid cancer comprising Brn3a

Country Status (1)

Country Link
KR (1) KR102175929B1 (en)

Also Published As

Publication number Publication date
KR20200099721A (en) 2020-08-25
KR102175929B1 (en) 2020-11-06

Similar Documents

Publication Publication Date Title
IL276808A (en) Compositions and methods for cancer treatment
EP3424505A4 (en) Preparation and composition for treatment of malignant tumors
IL268814A (en) Compositions and methods for treatment of cancer
GEP20217317B (en) Combination therapy for the treatment of cancer
FI3773689T3 (en) Antigenic peptides for prevention and treatment of cancer
EP4186519A4 (en) Interferon-based cancer treatment method and pharmaceutical composition
IL289787A (en) Antibody combinations for treatment of cancer in specific patients
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL290130A (en) Treatment of immune evasive tumors
EP4010022A4 (en) Compositions and methods for diagnosis and treatment of bladder cancer
IL274008A (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
IL288787A (en) Methods and compositions for improving outcomes of cancer patients
IL289251A (en) Methods and compositions for treatment of pancreatic cancer
IL255169A0 (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer
IL274007A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
IL272147A (en) Methods and compositions for the treatment of cancer
GB201820994D0 (en) Methods of treatment and diagnosis of tumours
KR102175929B9 (en) Brn3a Composition for diagnosis and treatment of thyroid cancer comprising Brn3a
FI3630112T3 (en) Combination of regorafenib and nivolumab for treating cancer
IL280262A (en) Compositions and methods for the treatment of cancer
EP3987032A4 (en) Methods and compositions for the treatment of cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
EP3794040A4 (en) Compositions and methods for diagnosis and treatment of cancer
IL276228A (en) Compounds and compositions for the treatment of pain
KR102373488B9 (en) Composition for immune enhancing or preventing or treating of cancer

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
G170 Re-publication after modification of scope of protection [patent]